Glucomust-PM Tablet ER is a combination oral antidiabetic medication formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glibenclamide 5 mg, Metformin 500 mg, and Pioglitazone 15 mg, each contributing distinct mechanisms to optimize blood glucose regulation. Glibenclamide, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, thereby reducing insulin resistance. Pioglitazone, a thiazolidinedione, further enhances insulin sensitivity in adipose tissue, muscle, and the liver by activating peroxisome proliferator-activated receptor gamma (PPAR-γ). The extended-release formulation ensures a sustained therapeutic effect, promoting better patient compliance through reduced dosing frequency. Glucomust-PM is indicated for patients inadequately controlled on monotherapy or dual therapy, providing a comprehensive approach to managing hyperglycemia. It should be used adjunctively with diet and exercise to achieve optimal glycemic control. Caution is advised in patients with hepatic or renal impairment, heart failure, or a history of lactic acidosis. Regular monitoring of blood glucose levels, liver function, and renal parameters is recommended during therapy. Glucomust-PM Tablet ER offers an effective, multi-targeted strategy for managing type 2 diabetes mellitus.